Vanguard Global Advisers’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$414K Buy
11,646
+144
+1% +$4.35K ﹤0.01% 2177
2026
Q2
$274K Hold
11,502
– – ﹤0.01% 2369
2026
Q1
$282K Buy
+11,502
New +$377K ﹤0.01% 2273

Other funds holding CSTL

Vanguard Global Advisers's CSTL Position: Q3 2026 in Review

Vanguard Global Advisers increased its Castle Biosciences (CSTL) stake by 1.3% in Q3 2026, buying an estimated $4.35K and bringing the position to 11,646 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Vanguard Global Advisers first reported a position in CSTL in Q1 2026 and has held it in 3 quarters since. 201 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Vanguard Global Advisers held 11,646 shares of Castle Biosciences worth $414K as of Q3 2026.
  • Vanguard Global Advisers bought 144 Castle Biosciences shares in Q3 2026, an estimated $4.35K.
  • Castle Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2177 holding.
  • Vanguard Global Advisers first reported a position in Castle Biosciences in Q1 2026 and has held it in 3 quarters since.
  • 201 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.